Multidrug resistant Pseudomonas aeruginosa has become an urgent medical threat due to a lack of effective treatment strategies. Although colistin has been brought back as a last line of treatment, P. aeruginosa is able to reduce this drug’s efficacy by modifying its outer membrane using the enzymes encoded in the arnBCADTEF operon. We aim to block this resistance pathway by developing inhibitors of ArnA, the first committed step in the membrane-modification pathway. A combination therapy using colistin and an effective ArnA inhibitor will maintain the efficacy of this last-line antibiotic.

Increase colistin susceptibility in antibiotic resistant Pseudomonas aeruginosa

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.